;(I);and crystalline forms thereof (I) and (II), wherein said crystalline forms have characteristic peaks expressed in degrees 2θ(±0.2 2θ), at 21.563, 21.156, 23.295, 21.955 and 20.838 on an X-ray powder diffraction pattern obtained with radiation of Cu-Kα for form (I) and at 3.274, 21.481, 23.887 for form (II).;EFFECT: said rotigotine behenate is characterized by the ability to maintain its effective concentration in plasma for a long period of time, has high bioavailability and can provide the effect of prolonged, effective and stable release.;19 cl, 10 dwg, 6 tbl, 9 ex"/>
ROTIGOTINE BEHENATE, METHOD FOR PRODUCTION AND USE THEREOF
首页>
外国专利>
ROTIGOTINE BEHENATE, METHOD FOR PRODUCTION AND USE THEREOF
ROTIGOTINE BEHENATE, METHOD FOR PRODUCTION AND USE THEREOF
展开▼
机译：山HEN酸罗替考汀，其生产方法和用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: chemistry.;SUBSTANCE: invention relates to rotigotine behenate represented by formula (I):; ;(I);and crystalline forms thereof (I) and (II), wherein said crystalline forms have characteristic peaks expressed in degrees 2θ(±0.2 2θ), at 21.563, 21.156, 23.295, 21.955 and 20.838 on an X-ray powder diffraction pattern obtained with radiation of Cu-Kα for form (I) and at 3.274, 21.481, 23.887 for form (II).;EFFECT: said rotigotine behenate is characterized by the ability to maintain its effective concentration in plasma for a long period of time, has high bioavailability and can provide the effect of prolonged, effective and stable release.;19 cl, 10 dwg, 6 tbl, 9 ex
展开▼
机译：发明领域本发明涉及由式（I）表示的罗替戈汀山hen酸酯： ;（I）;及其晶形（I）和（II），其中所述晶形在X射线粉末上具有在21.563、21.156、23.295、21.955和20.838处以2θ（±0.22θ）度表示的特征峰。 （I）形式的Cu-Kα辐射和（II）形式的3.274、21.481、23.887辐射获得的衍射图;效果：所述罗替戈汀山hen酸酯的特征是能够在血浆中长期保持其有效浓度时间，高生物利用度并可以提供延长，有效和稳定的释放效果。; 19 cl，10 dwg，6 tbl，9 ex
展开▼
